このエビデンス概要は医学的助言ではありません。研究と執筆のための、出典付き文献検索ドラフトです。引用または応用する前に、必ず原論文を確認してください。
研究上の問い
GLP-1受容体作動薬は減量アウトカムを改善するのか？
短い回答
返された文献は、薬剤、用量、追跡期間、対象集団、有害事象報告を確認して読む必要があります。
検索条件と結果
- 検索した主張: GLP-1受容体作動薬は減量アウトカムを改善する。
- 検索意図: GLP-1受容体作動薬と減量に関する出典付き生物医学論文を探す。
- 結果セット: この主張について LitSource が返した、出典付きの主要な生物医学論文です。
- 最終更新日: 2026-05-04
見つかった主な論文
| 論文 | 年 | ジャーナル | 出典 | エビデンススニペット |
|---|---|---|---|---|
| Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies. | 2025 | Diabetology & metabolic syndrome | PMID 40846976 | According to a 2025 retrospective cohort study, among people prescribed GLP-1 receptor agonists, active use of a digital weight management platform significantly improved weight loss outcomes (e.g., an additional 3.5% p… |
| Weight-centric prevention of cancer. | 2024 | Obesity pillars | PMID 38495815 | Newer glucagon-like peptide-1 (GLP-1) receptor agonists (i.e., semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) co-agonists (i.e., tirzepatide) have showed significantly superior weight loss outcomes… |
| Digital engagement enhances dual GIP/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. | 2026 | Diabetes, obesity & metabolism | PMID 41145379 | The latest landmark trials of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown substantial weight-loss outcomes. |
| The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment. | 2025 | Cureus | PMID 40497223 | The recent emergence and widespread adoption of potent anti-obesity medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and dual incretin agonists such as tirzepatide, have creat… |
| Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study. | 2025 | Journal of medical Internet research | PMID 40164173 | This study provides compelling evidence that engagement with digital health platforms significantly enhances weight loss outcomes among individuals undergoing pharmacotherapy with GLP-1 receptor agonists for obesity man… |
| Practice Patterns in Body Mass Index Optimization Among US Arthroplasty Surgeons: Results of a National American Association of Hip and Knee Surgeons Survey. | 2026 | Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews | PMID 41706617 | A retrospective cohort study analyzed the use of Glucagon-like Peptide-1 (GLP-1) receptor agonists in 268,504 THA and 386,356 TKA patients, finding that preoperative GLP-1 use (n = 1044 for THA; n = 2095 for TKA) was as… |
| Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. | 2024 | Obesity reviews : an official journal of the International Association for the Study of Obesity | PMID 38320760 | Glucagon-like peptide 1 (GLP-1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes. |
| A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. | 2023 | Life (Basel, Switzerland) | PMID 37109541 | In this analysis, we emphasize the six GLP-1 receptor agonists' remarkable weight loss outcomes across a range of clinical research programs. |
エビデンスが支持しているように見える点
上記の論文は、この主張に対する LitSource の出典付き検索で返された候補文献です。引用する前に、ハイライトされたスニペットを確認し、原論文を開いて文脈を確認してください。
まだ不確かな点
このドラフトは臨床的確実性を順位付けせず、システマティックレビューの方法を置き換えず、この主張を医療判断に使うべきかを決めるものでもありません。引用前に研究デザイン、対象集団、介入内容、効果量、新しさを確認してください。
LitSource でこの検索を試す
この主張を LitSource に貼り付けると、検索を再実行し、更新されたエビデンススニペットを確認し、引用をエクスポートできます。